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Adjuvant chemo-hormonal therapy 
with cyclophosphamide, doxorubicin 
and 5-fluorouracil (CAF) with or 
without medroxyprogesterone acetate 
for node-positive cancer patients. 
Update at 7-year follow-up
The Comprehensive Cancer Center Limburg trial 82-01 is a 
prospective randomized investigation of the value of the 
addition of high-dose medroxyprogesterone acetate (MPA) 
to CAF chemotherapy in patients with node-positive (N+) 
operable breast cancer (T1-3) N J. The results of 408 evalu­
able patients, after a median follow-up of 42 months, have 
been published in Annals o f Oncology [1] and can be sum­
marized as follows: high dose MPA ameliorates CAF side 
effects and reduces the risk of metastatic disease in elderly 
breast cancer patients. Patients > 60  years benefitted most 
from MPA treatment, in particular if freedom from distant 
metastasis was taken as endpoint (p = 0.02). Overall survival 
(OS) showed a significant advantage in patients >55 years 
(p «  0.002). In this letter we report the updated results after a 
follow-up of 7 years.
After a median follow-up of 84 months the conclusions of 
the study remain unchanged. No differences in disease-free 
survival (DFS), distant-metastasis-free survival or OS were 
found for the patients as a whole (p-values were 0.12, 0.12 
and 0.18, respectively). OS curves of all patients whether 
treated or not with MPA are shown in Fig. 1. Subset analysis 
revealed a significantly better DFS for the patient group aged 
between 40 and 60 years than for the group < 40  or >60  
years (p = 0.002). This difference is MPA treatment inde­
pendent.
Patients > 60  years showed a significantly longer DFS and 
OS when MPA was added to CAF chemotherapy (p-values
0.05 and 0.008, respectively) (Fig. 2).
By contrast, in the subgroup of patients < 40  years, the 
addition of MPA to chemotherapy proved detrimental: the 
relative risk (RR) for relapse of breast cancer was 1.6 versus 
1.1 for patients with and without MPA, respectively, while the 
RR in the group > 60  years was lower (0.7 vs. 1.0), in favor of 
the MPA-treated group.
In conclusion, this trial suggests a beneficial effect of MPA 
in combination with chemotherapy in elderly patients (>60  
years). The beneficial effect may in part be explained by 
higher estrogen receptor (ER) levels in elderly breast cancer 
patients. In young breast cancer patients (<40 years) MPA 
added to adjuvant chemotherapy has a detrimental effect, 
possibly caused by its protective effect on ovarian function 
during CAF chemotherapy [2], which prevents CAF chemo- 
therapy-induced ovarian ablation. An alternative explanation 
may be that MPA reduces the cellular ER and PgR content in 
breast cancer cell lines [3]. This down-regulation of ER con­
tent in pre-menopausal breast cancer patients could have a
year« from diagnoses
Fig. I  O verall Survival (O S) curve for all node-positive patients in 
both treatment arms. N o  statistically significant differences between  
the two treatm ent arms (p  «  0.12). For both survival curves 95%  
confidence b ounds are drawn,
Overall Survival in Patients Older than 60 Years 
CAF versus CAF+MPA, with 95% Pointwise Confidence Intervals
years from diagnoses
Fig. 2. Overall Survival (O S) curve for both treatment arms in pa­
tients > 6 0  and < 7 0  years. D ifferences in favor of the C A F  +  MPA 
treatment arm (p =  0 .0 0 8 ). For both survival curves 95%  simultane­
ous con fid en ce bounds are drawn.
negative influence of endogenous estrogen on the tumor-cell 
cycle (lower percentage of tumor cells in the proliferative 
phase) causing a reduced effect of adjuvant chemotherapy on 
tumor cells in premenopausal patients.
The previously described bone marrow protective effect 
of MPA [1J is supported by two recent studies demonstrating 
in vitro that MPA causes a cell-cycle arrest of hematopoietic 
precursors which protects them from the toxicity of chemo­
therapy [4], and in vivo that MPA induces a mitotic arrest in 
hematopoietic stem cells [5].
The combination of MPA and chemotherapy deserves 
further exploration in postmenopausal breast cancer pa­
tients.
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